关节型银屑病,抗风湿药,生物制剂 ," /> 关节型银屑病,抗风湿药,生物制剂 ,"/> psoriatic arthritis,disease-modifying antirheumatic drugs,biologic agents ,"/> <p class="MsoNormal"> 关节病型银屑病的治疗进展

中国麻风皮肤病杂志 ›› 2017, Vol. 33 ›› Issue (4): 245-248.

• 综述 • 上一篇    下一篇

关节病型银屑病的治疗进展

熊菲1,2  杨青2   

  1. 1济南大学山东省医学科学院医学与生命科学学院，济南，250062

    2山东省皮肤病性病防治研究所，济南，250022

  • 出版日期:2017-04-15 发布日期:2018-12-19
  • 通讯作者: 杨青，E-mail: yangqing79@126.com

Update of pharmacological treatment of psoriatic arthritis

XIONG   Fei1,2, YANG Qing2   

  1. 1. School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan 250062, China; 2. Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, 250022, China

  • Online:2017-04-15 Published:2018-12-19
  • Contact: YANG Qing, E-mail: yangqing79@126.com

PDF (PC)

134

摘要：

关节病型银屑病是一种累及皮肤和关节的慢性炎症性疾病，治疗药物包括非甾体抗炎药,免疫抑制剂和生物制剂，本文就其疗效及不良反应进行综述

关键词: 关节型银屑病')">

关节型银屑病, 抗风湿药, 生物制剂

Abstract:

Psoriatic arthritis (PsA) is a chronic inflammatory disease, which affects the skin and joints. Therapy drugs include nonsteroidal anti-inflammatory agents (NSAID), disease-modifying antirheumatic drugs (DMARDs) and biologic agents. The effects and adverse reactions of those drugs in the treatment of PsA were reviewed in this article

Key words: psoriatic arthritis')">

psoriatic arthritis, disease-modifying antirheumatic drugs, biologic agents